Literature DB >> 12056546

Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors.

R Bigoni1, G Caò, A Rizzi, H Okawa, D Regoli, D Smart, D G Lambert.   

Abstract

We have studied the effects of naloxone benzoylhydrazone (NalBzoH) at recombinant human OP4 receptors expressed in Chinese hamster ovary (CHO) cells (CHOhOP4) and native OP4 sites in isolated tissues from various species. In CHOhOP4 membranes, nociceptin (NC) and NalBzoH displaced [125I]Tyr14-NC with pKi values of 10.1 and 7.3. In the presence of 100 microM GDP, NC stimulated GTPgamma35S binding (pEC50 = 8.5). NalBzoH was ineffective but antagonized the effects of NC (pA2 = 6.9). At 5 microM GDP, there was an increase in potency (pEC50 = 9.3) and efficacy (4.3-fold) of NC. NalBzOH was a partial agonist (pEC50 = 7.0, Emax = 13% relative to NC). In CHOhOP4 cells, NC and NalBzoH inhibited cAMP formation with pEC50 and Emax values of 9.8 and 100% and 6.0 and 44%, respectively. In the rat vas deferens, NalBzoH (10 microM) did not modify electrically induced twitches but competitively antagonized the inhibitory action of NC (pA2 = 6.2). In the mouse vas deferens (mVD) and guinea pig ileum (gpI), NalBzoH inhibited twitches with pEC50 and Emax values of 7.6 and 78% and 8.5 and 77%, respectively. The effect of 3 microM NalBzoH was fully inhibited by 3 microM naloxone in mVD and 30 microM in gpI. Under these conditions, NalBzoH antagonized the actions of NC in both preparations with pA2 values of 6.3 and 6.8, respectively. Collectively, these data demonstrate that NalBzoH is a nonselective OP4 ligand with system-dependent behaviour.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12056546     DOI: 10.1139/y02-040

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  10 in total

1.  Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.

Authors:  K Flau; A Redmer; S Liedtke; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.

Authors:  John McDonald; David G Lambert
Journal:  Br J Pharmacol       Date:  2010-02-10       Impact factor: 8.739

3.  Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.

Authors:  Maria C Olianas; Danilo Concas; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

4.  UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.

Authors:  J McDonald; G Calo; R Guerrini; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-15       Impact factor: 3.000

5.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

6.  Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.

Authors:  Alexander Kuzmin; Johan Sandin; Lars Terenius; Sven Ove Ogren
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

7.  Panicolytic-like effects caused by substantia nigra pars reticulata pretreatment with low doses of endomorphin-1 and high doses of CTOP or the NOP receptors antagonist JTC-801 in male Rattus norvegicus.

Authors:  Juliana Almeida da Silva; Audrey Franceschi Biagioni; Rafael Carvalho Almada; Renato Leonardo de Freitas; Norberto Cysne Coimbra
Journal:  Psychopharmacology (Berl)       Date:  2017-08-30       Impact factor: 4.530

8.  G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.

Authors:  Pierluigi Onali; Maria C Olianas
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

9.  Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.

Authors:  J McDonald; T A Barnes; H Okawa; J Williams; G Calo'; D J Rowbotham; D G Lambert
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

Review 10.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

Authors:  Nurulain Zaveri
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.